Race Oncology highlights impressive bisantrene clinical data | News Direct

Race Oncology highlights impressive bisantrene clinical data

Race Oncology Ltd
News release by Race Oncology Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | November 07, 2023 12:15 PM Eastern Standard Time

Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith discusses with Proactive impressive Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients. Administered over four days, the drug combination induced a clinical response in 40% of evaluable patients with five patients receiving a potentially curative stem cell transplant.

“To see such meaningful clinical responses in a group that would typically be receiving palliative care is striking," said Smith.

"It is also encouraging that the safety profile was manageable, even for this advanced patient population.

"These are highly positive outcomes in a heavily pretreated patient population.”



Contact Details


Proactive Investors


Gregg Castano


+1 203-762-5649



project media


Race Oncology LtdbiotechAsxproactiveAustraliaproactiveInvestors